Skip to content
OpenCapital
Get started

AptarGroup ATR Pharma — Restructuring Charges

Discontinued — last reported Q1 '26

Similar metrics at other companies

PPG Industries logo
PPGCorporate — Restructuring Charges
$10M—
Zoetis logo
ZTSManufacturing, Research, Corporate — Restructuring Charges
$10.5M+200%
STERIS logo
STEHealthcare Member — Restructuring Charges
$33.82M—
TEC
TECHCorporate — Restructuring Charges
$688K+136%
Entegris logo
ENTGAPS — Restructuring Charges
$1M-83.3%
STERIS logo
STEHealthcare and Life Sciences — Restructuring expenses
$4.75M—

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Cash & equivalents$225.0M+78.8%
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$7.68B-17.9%
Enterprise value$8.89B-13.9%
P/E19.9×-5.4×
P/S2×-0.6×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The official record: AptarGroup’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's pharma — restructuring charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AptarGroup's pharma — restructuring charges?
AptarGroup (ATR) reported pharma — restructuring charges of $5K in Q1 2026.
How has AptarGroup's pharma — restructuring charges changed year-over-year?
AptarGroup's pharma — restructuring charges decreased by 97.4% year-over-year, from $190K to $5K.
What does pharma — restructuring charges mean?
Expenses related to reorganizing or streamlining the Pharma segment's operations.
How do you interpret pharma — restructuring charges?
High charges may signal short-term pain for long-term efficiency gains, while persistent high charges could indicate ongoing operational instability.
How does pharma — restructuring charges compare across companies?
Similar to restructuring costs reported by other industrial and pharmaceutical packaging companies undergoing operational transformation.